Cargando…

P048: Predictors of risk of relapse in classic Hodgkin lymphoma by flow cytometry

Detalles Bibliográficos
Autores principales:	Fromm, Jonathan, Tang, Claire, Naresh, Kikkeri N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Genomics, Biology & Microenvironment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621501/ http://dx.doi.org/10.1097/01.HS9.0000890760.14302.02

Ejemplares similares

T026: Characterization of cancer-associated fibroblasts in classical Hodgkin lymphoma
por: Karihtala, Kristiina, et al.
Publicado: (2022)

P054: The Kinase CK2 is deregulated and targetable in classical Hodgkin Lymphoma
por: Visentin, Andrea, et al.
Publicado: (2022)

P038: HLA expression patterns of Hodgkin-Reed-Sternberg cells shape a spatially arranged tumor microenvironment in classical Hodgkin lymphoma
por: Müller-Meinhard, Berit, et al.
Publicado: (2022)

P032: Circulating immune biomarkers in classical Hodgkin lymphoma in relation to tumor burden and response to treatment.
por: Mulder, Tom A., et al.
Publicado: (2022)

P044: PIM kinases support protumoral and immunosuppressive phenotype and functions of macrophages in classical Hodgkin Lymphoma
por: Szydłowski, Maciej, et al.
Publicado: (2022)

P052: Targeting CSN5/JAB1 oncogene in classical Hodgkin Lymphoma (cHL)
por: Xagoraris, Ioanna, et al.
Publicado: (2022)

P041: Low percentage of T lymphocytes in Hodgkin’s Lymphoma lymph nodes, measured by flow cytometry, is associated with inferior progression free survival regardless of negative interim pet scan status
por: Korin, Laura, et al.
Publicado: (2022)

P035: CRISPR/Cas9-mediated knockout reveals an important role of CD30 in Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma
por: Kilian, Annika L., et al.
Publicado: (2022)

P049: Reduced features of T-cell activation before and during anti-PD-1 treatment in classical Hodgkin lymphoma
por: Seifert, Nicole, et al.
Publicado: (2022)

P051: Serum procalcitonin levels in newly diagnosed classical Hodgkin Lymphoma (cHL): Correlation with other inflammatory biomarkers
por: Piperidou, Alexia, et al.
Publicado: (2022)

P034: Correlation between MTV, TLG and Serum TARC Concentration in Classical Hodgkin Lymphoma during First-Line Treatment
por: Romano, Ilaria, et al.
Publicado: (2022)

P043: Molecular pathogenesis of Hodgkin lymphoma
por: Beeck, Lilian, et al.
Publicado: (2022)

P053: The cGAS-STING anti-tumor immune response pathway as a potential therapeutic target in classical Hodgkin Lymphoma (cHL)
por: Xagoraris, Ioanna, et al.
Publicado: (2022)

P055: Validation of the tumor cell-specific rearranged IgG-encoding circulating cell-free DNA for the treatment response monitoring in patients with classic Hodgkin lymphoma
por: Buhtoiarov, Ilia, et al.
Publicado: (2022)

T028: Single-cell RNA sequencing reveals the interplay between circulating CD4 T cells, B cells and cancer-associated monocytes in classic Hodgkin lymphoma treated with PD-1 blockade
por: Paczkowska, Julia, et al.
Publicado: (2022)

P047: Predictive role of the Hodgkin lymphoma-associated cytokines: a prospective study of the Czech Hodgkin Study Group
por: Prochazka, Vit, et al.
Publicado: (2022)

P045: Plasma proteome profiling of cardiotoxicity in patients with Hodgkin lymphoma
por: Ulfstedt, Johan Mattsson, et al.
Publicado: (2022)

P046: Preclinical evaluation of novel repurposed drug combinations in Hodgkin lymphoma
por: Lohmann, Mia, et al.
Publicado: (2022)

P040: LINE-1 reverse transcriptase activity in Hodgkin lymphoma cells
por: Wadel, Annika, et al.
Publicado: (2022)

P042: Metabolic regulation of adaptive response to arginine deprivation in Hodgkin Lymphoma
por: Romano, Alessandra, et al.
Publicado: (2022)

P033: Clinical significance of the severity of THRLBCL-like areas in nodular lymphocyte predominant Hodgkin lymphoma
por: Shupletsova, Irirna, et al.
Publicado: (2022)

P056: Variants of the transcription factor ONECUT2 regulate gene expression in Hodgkin Lymphoma cells
por: Lein, Patricia, et al.
Publicado: (2022)

P030: Baseline IgM amount can identify patients with adverse outcome despite a PET-2 adapted treatment in classical Hodgkin Lymphoma: results from a real-life single-center study i
por: Romano, Alessandra, et al.
Publicado: (2022)

P036: Detection of recurrent somatic variants in cell-free DNA as a tool for disease monitoring in Hodgkin lymphoma
por: Grohmann, Jan, et al.
Publicado: (2022)

T027: High serum levels of Thymus and Activation Related Chemokine (TARC) precede Hodgkin lymphoma diagnosis by several years
por: Diepstra, Arjan, et al.
Publicado: (2022)

P039: HLA expression status and prognostic impact of B-cell content in patients with early-stage unfavorable Hodgkin lymphoma
por: Grund, Johanna, et al.
Publicado: (2022)

P037: High breadth whole exome sequencing of circulating tumor DNA identifies novel recurrent genetic alterations in Hodgkin lymphoma
por: Mammadova, Laman, et al.
Publicado: (2022)

P031: CD4+ T cells in close proximity to Hodgkin-Reed Sternberg cells are antigen experienced, polyclonal and display an exhausted phenotype
por: Veldman, Johanna, et al.
Publicado: (2022)

P029: Are Reed-Sternberg cells stuck in mitosis by short nucleoplasmic bridges as a consequence of centromeric instability?
por: M’Kacher, Radhia, et al.
Publicado: (2022)

P050: Reed-Sternberg cells accelerate glycolytic and mitochondrial metabolism of tumor microenvironment cells
por: Kurlapski, Michał, et al.
Publicado: (2022)

Flow Cytometric Detection of the Classical Hodgkin Lymphoma: Clinical and Research Applications
por: Roshal, Mikhail, et al.
Publicado: (2011)

MEF2B is the ideal immunohistochemical marker to highlight neoplastic LP cells in nodular lymphocyte‐predominant Hodgkin lymphoma
por: Torabi, Alireza, et al.
Publicado: (2023)

Flow cytometry assessment of reactive T‐cells distinguishes classic Hodgkin lymphoma from benign lymphadenopathy in children
por: Gao, Hui, et al.
Publicado: (2022)

Optimizing checkpoint inhibitors therapy for relapsed or progressive classic Hodgkin lymphoma by multiplex immunohistochemistry of the tumor microenvironment
por: Carbone, Antonino, et al.
Publicado: (2019)

Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma
por: Voorhees, Timothy J, et al.
Publicado: (2020)

Checkpoint Inhibitors in Relapsed/Refractory Classical Hodgkin Lymphoma
por: Tarekegn, Kidist, et al.
Publicado: (2021)

Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma
por: Johnston, Patrick B., et al.
Publicado: (2018)

Novel Agents For Relapsed and Refractory Classical Hodgkin Lymphoma: A Review
por: Zhang, Yujie, et al.
Publicado: (2022)

Optimizing Treatment for Relapsed/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy
por: Randall, Michael P., et al.
Publicado: (2023)

High number of kinome‐mutations in non‐small cell lung cancer is associated with reduced immune response and poor relapse‐free survival
por: Helland, Å., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_fk2sti1ujif1bk39ob8rsa9nh3